Navigating Clinical Trials in Central and Eastern Europe 2026

The clinical development landscape is evolving at an unprecedented pace. Rising costs, increasing trial complexity, and intense competition for patients are placing immense pressure on drug developers to make smarter, more efficient decisions.

For the 2026 edition of Industry Pages, Palleos delivers its most comprehensive analysis yet. Drawing on the latest data from the FDA, EMA, and clinical trial registries, this report provides an essential guide for pharmaceutical executives, clinical operations leaders, and CRO partners looking to optimize their global development strategies.

Here’s what you’ll learn inside:

• Why CEE is the strategic choice for 2026: Discover how conducting studies in the region can reduce overall costs by up to 50% compared to the US, while maintaining the highest standards of data quality and regulatory compliance.
• The region’s critical role in global approvals: In 2025, 33 out of 46 novel drugs approved by the FDA – 72% – and 27 out of 38 new medicines recommended by the EMA – 71% – were tested at clinical trial sites in Central and Eastern Europe, underscoring the region’s vital contribution to bringing new therapies to market.
• In-depth country profiles: We provide detailed analyses of 14 key markets, including Germany, Poland, the Czech Republic, Hungary, Romania, Bulgaria, Ukraine, Serbia, the Baltics, and more.
• Navigating the new regulatory era: Get a comprehensive guide to the finalized ICH E6(R3) GCP guideline and the fully migrated EU Clinical Trials Information System (CTIS), including practical strategies for compliance and faster trial approvals.

Featured insight: Poland’s emergence as a powerhouse.
Poland has solidified its position as a clinical research leader. In 2025, the country initiated 520 new clinical studies, and 27 of the 46 FDA-approved novel drugs incorporated data from Polish sites. With over 1,520 certified clinical trial sites and patient enrollment timelines averaging 40% faster than Western Europe, Poland offers a compelling model of efficiency and scale.

Ready to make Central and Eastern Europe the cornerstone of your clinical development success in 2026 and beyond?

Download the 2026 Industry Pages Report →